InsidersTradesSigma
Longeveron Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Longeveron Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Longeveron Inc. has recorded 18 reports. Market capitalisation: €23.1m. The latest transaction was disclosed on 5 January 2022 (Retenue fiscale). Among the most active insiders: Green Geoff. All data is free.
18
Insider Decl.
0
Thresholds
€48,235
6 ops.
Buy Volume
·
0 ops.
Sell Volume
55Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,295 of 25,921 companies
22.1
score / 100
Value2
Quality43
FCF yld-83%
Earn yld-98%
EV/EBITDA·
ROE-135%
Gross mgn67%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 5 January 2022
Declarations18 total
3,979 shares@ US$12.0923.0% of flowCommon StockSEC:0001214659-22-000336
1,736 shares@ US$12.0919.8% of flowCommon StockSEC:0001214659-22-000338
3,316 shares@ US$12.0921.8% of flowCommon StockSEC:0001214659-22-000335
2,500 shares@ US$3.6957.9% of flowCommon stockSEC:0001214659-21-010469
Ideal exit: 9 Jul 2022 (T+270)
1,000 shares@ US$3.811.8% of flowCommon stockSEC:0001214659-21-010468
Ideal exit: 10 Jul 2022 (T+270)
3,900 shares@ US$3.45100.0% of flowCommon stockSEC:0001214659-21-010459
Ideal exit: 8 Jul 2022 (T+270)
1,750 shares@ US$3.343.1% of flowCommon stockSEC:0001214659-21-010371
Ideal exit: 4 Jul 2022 (T+270)
1,985 shares@ US$3.3842.1% of flowCommon stockSEC:0001214659-21-010370
Ideal exit: 4 Jul 2022 (T+270)
5,000 shares@ US$3.3415.5% of flowCommon stockSEC:0001214659-21-010372
Ideal exit: 4 Jul 2022 (T+270)
38,752 shares@ US$3.6575.1% of flowCommon stockSEC:0001214659-21-010078
43,929 shares@ US$3.6575.2% of flowCommon stockSEC:0001214659-21-010076
19,052 shares@ US$3.6564.6% of flowCommon stockSEC:0001214659-21-010077
8,223 shares0Common StockSEC:0001214659-21-007759
12,335 shares0Common StockSEC:0001214659-21-007761
6,167 shares0Common StockSEC:0001214659-21-007758
5,000 shares0Common stockSEC:0001214659-21-006368
5,000 shares0Common StockSEC:0001213900-21-026420
5,000 shares0Common StockSEC:0001213900-21-026417
18 of 18 declarations
About Longeveron Inc.
Longeveron Inc. (ticker: LGVN) is a U.S.-based clinical-stage biotechnology company listed on the NASDAQ in the United States. From an equity analyst’s perspective, it is a high-risk, high-upside regenerative medicine name rather than a commercial-stage pharmaceutical company. The business is focused on developing cell-based therapies for chronic aging-related diseases and other serious conditions with limited treatment options. The company was originally formed in 2014 as a Delaware LLC and later converted into a corporation in 2021.\n\nLongeveron’s core asset is laromestrocel, marketed as Lomecel-B™, an allogeneic cell therapy derived from culture-expanded mesenchymal stem cells sourced from the bone marrow of young, healthy adult donors. The company’s scientific thesis is that the product may exert pro-vascular, pro-regenerative, anti-inflammatory, and tissue-repair effects, which could have applications across several difficult disease areas. Its main development programs currently center on three core indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and aging-related frailty. It is also advancing work in pediatric dilated cardiomyopathy (PDCM) and operates a treatment registry in The Bahamas under local ethical oversight for certain approved indications.\n\nIn competitive terms, Longeveron occupies a niche position in regenerative medicine and cellular therapeutics. The company is not competing as a broad diversified biotech platform; instead, it is highly concentrated around a small number of indications where the unmet medical need is significant and the regulatory pathway may support accelerated development. Its differentiation comes from the biological rationale for laromestrocel, early clinical signals across multiple studies, and a set of U.S. regulatory designations that can support development and potential commercialization. Management has also emphasized a partnership-led strategy to help fund development and reduce capital intensity.\n\nRecent corporate milestones have been important for the investment case. In 2025, Longeveron reported a positive Type B meeting with the FDA regarding a potential BLA pathway for laromestrocel in Alzheimer’s disease, following earlier positive data from its CLEAR-MIND Phase 2a study, which was presented at AAIC and published in Nature Medicine. The company also said its IND for PDCM became effective in July 2025, paving the way for a planned pivotal study. For HLHS, Longeveron continues to advance the ELPIS II trial and has highlighted the potential value of a pediatric Priority Review Voucher if the program succeeds. Overall, LGVN remains a speculative NASDAQ healthcare story in the United States, with value driven by clinical execution, regulatory progress, and financing discipline.
